CPIX logo

Cumberland Pharmaceuticals Inc.

CPIX
Healthcare|Drug Manufacturers - Specialty & Generic|US
$5.22
+0.21 (+4.19%)
Tangible Book / Share
$1.14
Cash / Share
$0.26
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (3)

Dec 2026
Est. completion
P4Subarachnoid Hemorrhage, Aneurysmal
Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage
NCT06119061n=20
Jul 2027
Est. completion
Early P1Glioblastoma
Imaging Acetadote Metabolism in Glioblastoma
NCT07387666n=10
Jan 2028
Est. completion
P2Idiopathic Pulmonary Fibrosis
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05571059n=128

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Mar 2026
P2
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
NCT02682511

Recent Press Releases

CPIX Investors Have Opportunity to Join Cumberland Pharmaceuticals Inc. Fraud Investigation with SBS Law
Nov 5, 2026 · Business Wire
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q3 2026 FINANCIAL RESULTS
Nov 3, 2026 · PRNewsWire
CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM
Oct 26, 2026 · PRNewsWire
Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results
Oct 23, 2026 · PRNewsWire
CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL
Oct 23, 2026 · PRNewsWire
CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM
Oct 19, 2026 · PRNewsWire

SEC Filings (49)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 26, 20268-KMaterial eventDocumentIndex
Oct 23, 20268-KMaterial eventDocumentIndex
Sep 11, 20268-K/AMaterial eventDocumentIndex
Aug 28, 20268-KMaterial eventDocumentIndex
Aug 7, 202610-QQuarterly reportDocumentIndex
Aug 4, 20268-KMaterial eventDocumentIndex
Jul 13, 20268-KMaterial eventDocumentIndex
Jul 1, 20268-KMaterial eventDocumentIndex
Jun 25, 20268-KMaterial eventDocumentIndex
May 26, 2026DEFM14AProxy / shareholder voteDocumentIndex
May 15, 2026PREM14ADocumentIndex
May 8, 202610-QQuarterly reportDocumentIndex
May 5, 20268-KMaterial eventDocumentIndex
Apr 24, 20268-KMaterial eventDocumentIndex
Apr 23, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 23, 20268-KMaterial eventDocumentIndex
Mar 12, 2026ARSAnnual report to holdersDocumentIndex
Mar 9, 2026DEFA14AProxy / shareholder voteDocumentIndex
Mar 9, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 9, 202610-KAnnual reportDocumentIndex
Mar 3, 20268-KMaterial eventDocumentIndex
Feb 9, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 4, 20268-KMaterial eventDocumentIndex
Nov 24, 20258-KMaterial eventDocumentIndex
Nov 7, 202510-QQuarterly reportDocumentIndex
Nov 4, 20258-KMaterial eventDocumentIndex
Oct 30, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Oct 21, 20258-KMaterial eventDocumentIndex
Aug 8, 202510-QQuarterly reportDocumentIndex
Aug 5, 20258-KMaterial eventDocumentIndex
May 15, 2025SC 13GPassive 5%+ stakeDocumentIndex
May 9, 202510-QQuarterly reportDocumentIndex
May 6, 20258-KMaterial eventDocumentIndex
Apr 28, 20258-KMaterial eventDocumentIndex
Apr 24, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Mar 19, 20258-KMaterial eventDocumentIndex
Mar 18, 2025ARSAnnual report to holdersDocumentIndex
Mar 10, 2025DEFA14AProxy / shareholder voteDocumentIndex
Mar 10, 2025DEF 14AProxy / shareholder voteDocumentIndex
Mar 7, 202510-KAnnual reportDocumentIndex